Mucopolysaccharidosis (MPS) Treatment Market Technology Advancement and Growth 2021 to 2027

“The Mucopolysaccharidosis (MPS) Treatment Market 2021 – 2027 report covers the important factors driving the growth of the market, untapped opportunities for manufacturers, trends and developments shaping the dynamics of the market and other insights across various key segments.”

Request Here For PDF Brochure

Global Mucopolysaccharidosis (MPS) Treatment Market, By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), By Treatment (Enzyme Replacement Therapy and Stem Cell Therapy ), By End User (Hospitals, Specialty Clinics, and Others), and By MPS Type (MPS-I, MPS-II, MPS-IV, MPS-VI, MPS-VII, and Others (MPS-III and MPS-IX)), is estimated to have a market valuation of US$ 1,566.5 million in 2020 and is expected to manifest a CAGR of 9.8% during the forecast period of 2020-2027, as mentioned in a new report published by Coherent Market Insights.

Driver

Focus of key players in the market on adopting inorganic strategies such as mergers and partnerships to extend their portfolio of products and consolidating their credibility in the market, is expected to propel growth of the global mucopolysaccharidosis (MPS) treatment market during the forecast period. In August 2020, the University of Florida along with Sareta Therapeutics Inc., had announced their strategic partnership to authorize research work for developing novel genetic drugs for treating the rare diseases such as mucopolysaccharidosis (MPS).

Impact of COVID-19 epidemic

Despite the COVID-19 pandemic, the large-scale research and development on novel products is expected to boost growth of the global mucopolysaccharidosis (MPS) treatment market. In July 2020, Abeona Therapeutics Inc., had announced that from two of its progressing clinical trial of MPS III Phase 1 and 2 on adeno-associated virus (AAV)-based gene therapies, ABO-102 and ABO-101, have shown promising results on the patients, with more enrolments can be expected in this program in future.

Furthermore, several initiatives are taken by governments to tackle COVID-19 epidemic. In May 2020, the Centers for Disease Control and Prevention (CDC) had begun to work with the All-of-America and All-of-Government approach to enhance the capacity of testing and its presence to increase case detection along with tracing of contacts across every state of the U.S. and aims to re-open the country through withdrawal of lockdown.

Browse 35 Market Data Tables and 34 Figures spread through 198 Pages and in-depth TOC on “Mucopolysaccharidosis (MPS) Treatment Market”- Global Forecast to 2027, by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), By MPS Type (MPS-I, MPS-II, MPS-IV, MPS-VI, MPS-VII, and Others (MPS-III and MPS-IX)), By End User (Hospitals, Specialty Clinics, and Others), and By Treatment (Enzyme Replacement Therapy and Stem Cell Therapy).

Major companies contributing in the market are offering a special compensation package to the patients. The Takeda Pharmaceutical Company Ltd., had introduced its Takeda OnePath Assistance Program to provide a personalized support to its patients. This programs looks after patients by creating easy access to the medicines for their treatments, which are generally produced by the company itself. This program offers insurance policies to its patients to bear the expenditure of their treatment, and also supports the patients suffering from MPS II (Hunter Syndrome). Hence, provision of compensations raise the customer base, which will further strengthen the positioning of the company globally.

Key Takeaways of the Global Mucopolysaccharidosis (MPS) Treatment Market:

Due to rising acquisitions and deals among key companies, the global mucopolysaccharidosis (MPS) treatment market is expected to manifest a CAGR of 9.8% during the forecast period. In August 2020, , the University of Florida along with Sareta Therapeutics Inc., had announced their strategic partnership to authorize research work for developing novel genetic drugs for treating the rare diseases such as mucopolysaccharidosis (MPS).

According to the treatment: Due to rising approval rates of enzyme replacement therapies for treatment of MPS, the enzyme replacement therapy segment is expected to hold its dominating position in the global mucopolysaccharidosis (MPS) treatment market in 2019. In October 2018, a biopharmaceutical company, Ultragenyx Pharmaceutical Inc., had received approval from Brazil’s National Health Surveillance Agency (ANVISA) for its Mepsevii (vestronidase alfa) to treat patients suffering from Mucopolysaccharidosis VII (MPS VII, Sly syndrome) irrespective of age.

Major Key Players Include In Mucopolysaccharidosis (MPS) Treatment Market: Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics Inc., Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.

Buy instant copy of this research report with Flat US $ 2000 Off@ – https://www.coherentmarketinsights.com/promo/buynow/4184

Main points in Mucopolysaccharidosis (MPS) Treatment Market Report Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Mucopolysaccharidosis (MPS) Treatment Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Mucopolysaccharidosis (MPS) Treatment Industry Impact

Chapter 2 Global Mucopolysaccharidosis (MPS) Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Mucopolysaccharidosis (MPS) Treatment (Volume and Value) by Type
2.3 Global Mucopolysaccharidosis (MPS) Treatment (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Mucopolysaccharidosis (MPS) Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Mucopolysaccharidosis (MPS) Treatment Market Analysis
Chapter 6 East Asia Mucopolysaccharidosis (MPS) Treatment Market Analysis
Chapter 7 Europe Mucopolysaccharidosis (MPS) Treatment Market Analysis
Chapter 8 South Asia Mucopolysaccharidosis (MPS) Treatment Market Analysis
Chapter 9 Southeast Asia Mucopolysaccharidosis (MPS) Treatment Market Analysis
Chapter 10 Middle East Mucopolysaccharidosis (MPS) Treatment Market Analysis
Chapter 11 Africa Mucopolysaccharidosis (MPS) Treatment Market Analysis
Chapter 12 Oceania Mucopolysaccharidosis (MPS) Treatment Market Analysis
Chapter 13 South America Mucopolysaccharidosis (MPS) Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Mucopolysaccharidosis (MPS) Treatment Business
Chapter 15 Global Mucopolysaccharidosis (MPS) Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology

Request for a Sample Report

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com